

HETEROCYCLES, Vol. 60, No. 5, 2003, pp. 1203 - 1209

Received, 21st January, 2003, Accepted, 28th February, 2003, Published online, 3rd March, 2003

FORMAL SYNTHESIS OF ANISOMYCIN

Meng-Yang Chang,^a Shui-Tein Chen,*^a and Nein-Chen Chang*^b


^a*Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan*

^b*Department of Chemistry, National Sun Yat-Sen University, Kaohsiung 804, Taiwan*

Abstract—A straightforward formal synthesis of anisomycin has been established starting from *trans*-4-hydroxyproline.

1. INTRODUCTION

The antibiotic anisomycin was first isolated from the fermentation broths of *Streptomyces griseolus* and *Streptomyces roseochromogenes* by Sobin and Tanner at Pfizer, Inc. in 1954.¹ Subsequently, it was found in two related strains, *Streptomyces* sp. No. 638 and SA 3097, by groups in Japan.²⁻³ This alkaloid's absolute stereochemistry has been firmly established as 2*R*,3*S*,4*S* by correlation of chemical structure with L-tyrosine,⁴ and its relative stereochemistry was elucidated by chemical, spectroscopic and X-Ray crystallographic means.⁵⁻⁷ Anisomycin is a valuable tool in molecular biology. It possesses strong and selective activity against pathogenic protozoa and several strains of fungi⁸⁻⁹ and has been used successfully in the clinics for the treatment of trichomonas vaginitis¹⁰⁻¹¹ and amoebic dysentery.¹²



anisomycin (**1**)


Recently, Kameyama, *et al.*, reported that anisomycin and its derivatives (3097-B1, 3097-B2 and 3097-C2) were employed as fungicides and to inhibit other pathogenic fungi in plants.³ Its structure-activity relationship has been reported.³ Anisomycin also found additional uses to inhibit effectively peptide bond formation on eukaryotic ribosomes.¹⁴ To date, the preparation of anisomycin has almost invariably relied on a pool of chiral starting materials and has often proceeded in modest yield.¹⁵⁻¹⁶ Therefore, there is a continuing need for other chiral materials to synthesize anisomycin. Here we report a straightforward synthesis of anisomycin using *trans*-4-hydroxyproline as a new chiral material.

2. RESULTS AND DISCUSSION

2.1 Retrosynthetic analysis of anisomycin (1)

Our approach to target molecule (1) is shown in Scheme 1. In 1989, Takano and his co-workers¹⁶ described a synthesis of anisomycin (1) in which compound (2) was the important intermediate. To increase total yield and to shorten the steps, we developed a straightforward route using *trans*-4-hydroxyproline (3), a commercial available starting material.

Scheme 1. Retrosynthetic analysis of anisomycin (1)




2.2. Formal synthesis of anisomycin (1)

The formal synthesis of anisomycin (1), as shown in Scheme 2, uses a facile strategy from *trans*-hydroxyproline (3). *N*-BOC-proline methyl ester (4) was readily obtained from 3 in two-step reactions of methylation with thionyl chloride and methanol in an ice bath and *t*-Boc-protection with di-*t*-butyl dicarbonate and sodium bicarbonate in a mixture of water and dioxane at room temperature. *N*-BOC-proline methyl ester (4) was silylated with *t*-butyldimethylsilyl chloride (TBSCl) and imidazole to give the resulting *O*-TBS-proline ester. Reduction of *O*-TBS-proline ester with sodium borohydride

(NaBH_4) in the presence of lithium chloride¹⁷ furnished alcohol (**5**). **5** was transformed into the aldehyde by Swern oxidation.¹⁸ Chain extension with the 4-methoxyphenyl anion derived by Grignard reaction of 4-bromoanisole and magnesium in anhydrous tetrahydrofuran provided the alcohol (**6**) as a mixture in the ratio of 1:1. Exposure of **6** to triethylsilane in trifluoroacetic acid caused simultaneous desilylation, debutoxycarbonylation, and reduction of the benzylic hydroxyl group, providing the pyrrolidine (**7**), which was *N*-protected with benzyloxycarbonyl chloride (CBZCl) to give the hydroxypyrrolidine (**2**).

Scheme 2. Formal synthesis of anisomycin (**1**)



3. CONCLUSION

In summary, the straightforward formal synthesis of anisomycin (**1**) from *trans*-4-hydroxyproline (**3**) to alcohol (**2**) in eight steps provided 56% overall yield.

4. EXPERIMENTAL

4.1. General. Methylene chloride and tetrahydrofuran were distilled prior to use. All other reagents and solvents were obtained from commercial sources and used without further purification. Reactions were routinely carried out under an atmosphere of dry nitrogen with magnetic stirring. Products in organic solvents were dried with anhydrous magnesium sulfate before concentration *in vacuo*. All reported melting temperatures were uncorrected.

4.2. (2*S*,4*R*)-1-*t*-Butoxycarbonyl-4-hydroxy-2-methoxycarbonylpyrrolidine (**4**)¹⁹

Thionyl chloride (2.50 g, 21.0 mmol) was added to a stirred solution of **3** (1.31 g, 10.0 mmol) in methanol

(20 mL) at $-78\text{ }^{\circ}\text{C}$ for 10 min. The mixture was stirred in an ice bath for 30 min then at rt for 30 min, followed by reflux for 3 h. Concentration *in vacuo* followed by azeotropic removal of water using benzene gave methyl 4-hydroxyproline-HCl (1.81 g, 100%). Sodium bicarbonate (1.68 g, 20.0 mmol) and di-*t*-butyl dicarbonate (2.4 g, 11.0 mmol) were added to a solution of the resulting product (1.81 g) in THF (20 mL) and water (20 mL) in an ice bath. After stirring at the same temperature for 2 h, the mixture was concentrated *in vacuo*. Ethyl acetate (40 mL) was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo*. The residue was purified by column chromatography (hexane/ethyl acetate=2/1) to yield **4** (2.25 g, 92%): viscous oil; $[\alpha]_{\text{D}} -57.4\text{ }^{\circ}$ (*c* 1.0, CH₃OH), [lit.,¹⁹ $[\alpha]_{\text{D}} -60.2\text{ }^{\circ}$ (*c* 1.0, CH₃OH)]; ¹H NMR (400 MHz, CDCl₃) δ 4.46-4.35 (m, 2H), 3.70 (s, 3H), 3.63-3.44 (m, 2H), 2.30-2.25 (m, 1H), 2.06-1.97 (m, 2H), 1.43 (br s, 9H); Anal. Calcd for C₁₁H₁₉NO₅ C, 53.87; H, 7.81. Found C, 53.68; H, 7.70.

4.3. (2*S*,4*R*)-1-*t*-Butoxycarbonyl-2-hydroxymethyl-4-[*t*-butyldimethylsilyloxy]pyrrolidine (**5**)²⁰

tert-Butyldimethylsilyl chloride (1.51 g, 10.0 mmol) and imidazole (1.0 g, 14.7 mmol) were added to a solution of **4** (2.2 g, 9.0 mmol) in DMF (10 mL) at rt. After stirring at the same temperature for 2 h, the mixture was concentrated *in vacuo*. Ethyl acetate (40 mL) was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo* to give the crude product (3.0 g, 93%). Without further purification, lithium chloride (1.22 g, 28.8 mmol), and sodium borohydride (1.09 g, 28.8 mmol) were added to a solution of the crude product (2.9 g) in THF (20 mL) and methanol (20 mL) at rt. After stirring at the same temperature for 12 h, the mixture was concentrated *in vacuo*. Ethyl acetate (40 mL) was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo*. The residue was purified by column chromatography (hexane/ethyl acetate=2/1) to yield **5** (2.6 g, 97%): oil; $[\alpha]_{\text{D}} -51.2\text{ }^{\circ}$ (*c* 1.0, CH₃OH); EI-MS: C₁₆H₃₃NO₄Si *m/z* (%) = 331; HRMS (EI, M⁺) calcd for C₁₆H₃₃NO₄Si 331.2179, found 331.2180; ¹H NMR (400 MHz, CDCl₃) δ 4.28-4.24 (m, 1H), 4.12-4.05 (m, 1H), 3.67 (dd, *J* = 2.5, 11.3 Hz, 1H), 3.52 (dd, *J* = 7.3, 11.3 Hz, 1H), 3.42 (dt, *J* = 2.0, 11.6 Hz, 1H), 3.31 (dd, *J* = 4.1, 11.6 Hz, 1H), 3.25 (br s, 1H), 1.96-1.90 (m, 1H), 1.65-1.58 (m, 1H), 1.45 (s, 9H), 0.84 (s, 9H), 0.36 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 80.38, 69.80, 66.96, 58.92, 55.99, 38.00, 28.42 (6x),

25.67, 17.92, -4.87 (2x); Anal. Calcd for C₁₆H₃₃NO₄Si C, 57.97; H, 10.03. Found C, 57.66; H, 9.79.

4.4. (2*S*,4*R*)-1-*t*-Butoxycarbonyl-2-{1-hydroxy-1-[4-methoxyphenylmethyl]}-4-[*t*-butyldimethylsilyloxy]pyrrolidine (**6**)

A solution of oxalyl chloride (200 mg, 1.56 mmol) in CH₂Cl₂ (10 mL) was mixed with dimethyl sulfoxide (200 mg, 2.56 mmol) together carefully at -78 °C. The solution was warmed to -40 °C for 5 min and recooled to -78 °C, and then a solution of **5** (400 mg, 1.21 mmol) in CH₂Cl₂ (5 mL) was added dropwise for 20 min followed by excess triethylamine (4 mL, 28.5 mmol) for 30 min. The reaction mixture was warmed to rt and poured into saturated aqueous ammonium chloride solution (2 mL), and concentrated. The residue was diluted with water (15 mL) and extracted with ethyl acetate (3 x 30 mL). The organic layer was washed with brine and water, dried, filtered and concentrated to produce crude product (362 mg). Without further purification, 4-methoxyphenylmagnesium bromide (1M in THF, 1.4 mL, 1.4 mmol) was added to a solution of the resulting crude aldehyde (362 mg, 1.1 mmol) in THF (10 mL) -78 °C. After stirring at the same temperature for 3 h, the mixture was concentrated *in vacuo*. Ethyl acetate (20 mL) was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo*. The residue was purified by column chromatography (hexane/ethyl acetate=2/1) to yield **6** (445 mg, 93%): viscous oil; EI-MS: C₂₃H₃₉NO₅Si m/z (%) = 437; HRMS (EI, M⁺) calcd for C₂₃H₃₉NO₅Si 437.2598, found 437.2592; ¹H NMR (400 MHz, CDCl₃) δ 7.25-7.20 (m, 2H), 6.88-6.75 (m, 2H), 4.81-4.72 (m, 1H), 4.50-4.20 (m, 3H), 3.76 (s, 3H), 3.52-3.34 (m, 1H), 3.30-3.15 (m, 1H), 1.60-1.94 (m, 2H), 1.37 (s, 9H), 0.92 (s, 9H), 0.05 (s, 6H).

4.5. (2*S*,4*R*)-1-Benzoyloxycarbonyl-2-[4-methoxyphenylmethyl]-4-hydroxypyrrolidine (**2**)¹⁶

A mixture of **6** (250 mg, 0.57 mmol), trifluoroacetic acid (1 mL), and triethylsilane (1.01 mL, 0.63 mmol) was stirred at rt for 15 h, and then the mixture was concentrated *in vacuo*. Ethyl acetate (20 mL) was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo* to give crude **7** (107 mg). Without further purification, a mixture of triethylamine (102 mg, 1.0 mmol) and benzyloxycarbonyl chloride (0.12 mL, 0.86 mmol) was added to a solution of the resulting **7** (107 mg) in THF (10 mL) in an ice bath. After stirring at the same temperature for 3 h, the mixture was concentrated *in vacuo*. Ethyl acetate (20 mL)

was added to the residue, and the solution was washed with 0.1N HCl, saturated sodium bicarbonate solution and brine, dried, filtered, then concentrated *in vacuo*. The residue was purified by column chromatography (hexane/ethyl acetate=1/1) to yield **2** (153 mg, 88%): oil; $[\alpha]_D -78.2^\circ$ (*c* 1.12, CHCl₃); EI-MS: C₂₀H₂₃NO₄ *m/z* (%) = 91 (100), 121 (23), 176 (46), 220 (43), 341 (4); HRMS (EI, M⁺) calcd for C₂₀H₂₃NO₄ 341.1627, found 341.1616; ¹H NMR (500 MHz, CDCl₃) δ 7.41-7.31 (m, 5H), 7.00 (br s, 2H), 6.79 (br d, *J* = 7.5 Hz, 2H), 5.25-5.16 (m, 2H), 4.23-4.20 (m, 2H), 3.78 (s, 3H), 3.58-3.48 (m, 1H), 3.30 (dd, *J* = 4.5, 12.0 Hz, 1H), 3.12-2.97 (m, 1H), 2.76-2.69 (m, 1H), 1.89-1.86 (m, 2H), 1.83 (br s, 1H); Anal. Calcd for C₂₀H₂₃NO₄ C, 70.36; H, 6.79. Found C, 70.61; H, 6.88.

The retention time of alcohol (**2**) was 19.67 min by an RP-HPLC analysis. Water and acetonitrile (H₂O/MeCN=5~95%, 0~30 min both containing 0.1% TFA) were used as the solvent system at a flow rate of 1.0 mlmin⁻¹ on a Nucleosil C18 column (4.6 x 250 mm) at rt.

5. ACKNOWLEDGEMENT

The authors would like to thank the National Science Council of the Republic of China for financial support.

6. REFERENCES

1. B. A. Sobin and F. W. Tanner, *J. Am. Chem. Soc.*, 1954, **76**, 4053.
2. S. Ishida, O. Yamada, F. Futatsuya, K. Ito, H. Yamamoto, and K. Munakata, *Proc. Int. Congr. IAMS 1st*, 1974, **3**, 641.
3. Y. Hosoya, T. Kameyama, H. Naganawa, Y. Okami, and T. Takeuchi, *J. Antibiot.*, 1993, **46**, 1300.
4. C. M. Wong, *Can. J. Chem.*, 1968, **46**, 1101.
5. J. J. Beereboom, K. Butler, F. C. Pennington, and I. A. Solomons, *J. Org. Chem.*, 1965, **30**, 2334.
6. J. P. Schaefer and P. J. Wheatley, *J. Org. Chem.*, 1968, **33**, 166.
7. K. Butler, *J. Org. Chem.*, 1968, **33**, 2136.
8. A. Jimenez and D. Vazquez, In *Antibiotics*, ed. by F. E. Hahn, Springer-Verlag, Berlin, 1979, pp. 1-19.

9. A. P. Grollman, *J. Biol. Chem.*, 1967, **242**, 3226.
10. W. W. Frye, J. G. Mule, and C. Swartzwelder, *Antibiot. Ann.*, 1955, 820.
11. T. Armstrong and O. Santa Maria, *Antibiot. Ann.*, 1955, 824.
12. V. M. Santander, A. B. Cue, J. G. H. Diaz, F. J. Balmis, G. Miranda, E. Urbina, J. Portilla, A. A. Plata, H. B. Zapata, V. A. Munoz, and L. M. Abreu, *Rev. Invest. Biol. Univ. Guadalajara*, 1961, **1**, 94.
13. M. Windholz, *The Merck Index*, 12th ed., Merck: Whitehouse Station, NJ, 1996, p. 710.
14. T. Korzybski, Z. Kowszyk-Gindifer, and W. Kurytowicz, *Antibiotics*, American Society of Microbiology, Washington, DC, 1978, Vol. 1, pp. 343-346.
15. A. N. Hulme and E. M. Rosser, *Org. Lett.*, 2002, **4**, 265 and references cited therein.
16. S. Takano, Y. Iwabuchi, and K. Ogasawara, *Heterocycles*, 1989, **29**, 1861.
17. Y. Hamada, M. Shibata, F. Sugiura, S. Kato, and T. Shioiri, *J. Org. Chem.*, 1987, **52**, 1252.
18. A. J. Mancuso, S. L. Huang, and D. Swern, *J. Org. Chem.*, 1978, **43**, 2480.
19. A. Lewis, J. Wilkie, T. J. Rutherford, and D. Gani, *J. Chem. Soc., Perkin Trans. 1*, 1998, 3777.
20. K. Tanaka, H. Iwabuchi, and H. Sawanishi, *Tetrahedron Asymm.*, 1995, **6**, 2271.